GlassScriptPhysician profile
Alison S Haffner
NPI 1952814113
$8,089.73
in general payments reported to CMS, 2019-2025
47 companies · $631 in 2025
The $631 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,102 · 2022: $1,721 · 2023: $1,621 · 2024: $1,016 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.54 |
| Education | $289.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,232.04 | 2021-2024 | Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $846.64 | 2021-2025 | Pomalyst, Opdivo |
| Astellas Pharma US INC | $488.50 | 2021-2025 | Padcev |
| Incyte Corporation | $482.60 | 2021-2023 | Jakafi |
| Janssen Biotech, INC. | $391.70 | 2021-2025 | Erleada, Carvykti, Rybrevant |
| Seagen INC. | $390.23 | 2021-2023 | Tukysa |
| Amgen INC. | $375.19 | 2021-2023 | Lumakras, Blincyto, Kyprolis |
| Alexion Pharmaceuticals, INC. | $367.66 | 2021-2022 | |
| Genzyme Corporation | $267.99 | 2021-2025 | |
| Genentech USA, INC. | $233.38 | 2023-2025 | Phesgo, Perjeta, Kadcyla |
| Pharmacyclics LLC, An Abbvie Company | $224.44 | 2021-2023 | Imbruvica |
| Celgene Corporation | $194.01 | 2021-2024 | Pomalyst, Reblozyl |
| Pharmacosmos Therapeutics INC. | $178.38 | 2021-2022 | |
| Pfizer INC. | $177.91 | 2021-2025 | |
| Glaxosmithkline, LLC. | $175.49 | 2021-2025 | Ojjaara, Jemperli, Zejula |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Haffner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.